CD133 was first characterized as CSC marker in glioblastoma (89) and later it was found to be widely expressed in tumor-initiating cells of different tumors (e.g., ovarian, liver, lung, pancreatic and prostate cancer) (90). This evidence concerns the gene PROM1 and glioblastoma.